TREACE MEDICAL CONCEPTS, INC. 8-K

What Happened

• Treace Medical Concepts, Inc. filed an 8‑K on May 20, 2026 reporting results from its Annual Meeting of Stockholders held May 19, 2026. Stockholders elected three Class II directors to three‑year terms (expiring at the 2029 annual meeting), approved an advisory vote on executive compensation, and ratified Grant Thornton LLP as the company’s independent registered public accounting firm for fiscal 2026.

Key Details

• Director elections (three‑year terms):
  • Lance A. Berry: For 33,804,407; Withheld 820,723; Broker non‑vote 13,516,432.
  • Elizabeth S. Hanna: For 30,856,965; Withheld 3,768,165; Broker non‑vote 13,516,432.
  • Jane E. Kiernan: For 33,587,226; Withheld 1,037,904; Broker non‑vote 13,516,432.
• Advisory (non‑binding) vote on executive compensation: For 32,785,505; Against 1,724,383; Abstain 115,242; Broker non‑vote 13,516,432.
• Ratification of auditor: Grant Thornton LLP ratified as independent registered public accounting firm for fiscal year ending December 31, 2026 — For 47,885,305; Against 120,733; Abstain 135,524.

Why It Matters

• The elected directors will shape the company’s governance and strategic oversight through 2029.
• The advisory approval of executive compensation indicates shareholder support (though non‑binding) for the company’s pay practices.
• Ratifying Grant Thornton ensures continuity of external audit services for fiscal 2026, which relates to financial reporting reliability.